Status:
COMPLETED
Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients
Lead Sponsor:
University of Campinas, Brazil
Conditions:
End-stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Sodium-glucose co-transporter 2 inhibitors (Sglt2i) attenuate the incidence of cardiovascular events in individuals with preserved or mildly reduced kidney function. Whether this benefit is also obser...
Eligibility Criteria
Inclusion
- Dialysis for 3 months or more prior to enrollment
- 18 years of age or older
- Signed the informed consent form
Exclusion
- Liver dysfunction
- Allergy to dapagliflozin
- Currently receiving a Sglt2i
Key Trial Info
Start Date :
April 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT05343078
Start Date
April 25 2022
End Date
October 1 2022
Last Update
March 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Campinas
Campinas, São Paulo, Brazil, 13083-887